BOSTON, Aug. 30, 2021 /PRNewswire/ -- Ginkgo
Bioworks, Inc. ("Ginkgo"), which is building the leading horizontal
platform for cell programming, today announced the signing of a
multi-program collaboration with Givaudan, the world's leading
Taste & Wellbeing and Fragrance & Beauty company.
Ginkgo, which recently announced a business combination with
Soaring Eagle Acquisition Corp. (Nasdaq: SRNG), serves customers
across industries seeking to develop new and better products.
Givaudan will leverage Ginkgo's long-established expertise in
enabling companies to develop bio-based products to produce a
number of innovative and sustainable ingredients through
fermentation.
Givaudan has chosen to leverage Ginkgo's extensive platform to
accelerate development and enhance Givaudan's portfolio of
ingredients. Through this collaboration, Givaudan plans to
sustainably deliver products such as those that are only available
in minute quantities in nature, using the natural world as
inspiration for an expanded creative palette.
"We are excited to work with Givaudan to enhance their palette
of ingredients used for their product development," said
Jason Kelly, CEO at Ginkgo Bioworks.
"Through this close collaboration, we will be able to help Givaudan
transform even the rarest and most complex nature-inspired
ingredients into more sustainable products for consumers. We
believe that biology has the power to enable better and more
sustainable products across many industries, from flavors and
fragrances, to pharmaceuticals, to farming."
"Givaudan has long prided itself on being a leader in
innovation," said Allison Haitz,
Biotechnology Program Director at Givaudan. "This collaboration
with Ginkgo Bioworks is the latest example of our commitment to
offering the highest quality, natural products to our customers
around the world. We are excited to use biology to unlock more
wonders of nature in a sustainable way."
The collaboration between Ginkgo and Givaudan spans multiple
programs, with the possibility of adding more in the future.
Companies across numerous industries use Ginkgo's platform to find
more effective, environmentally friendly ways to create products
including food ingredients, flavors, cosmetics, medicines, and
more. By enabling the design of organisms that can produce valuable
biological products, Ginkgo helps accelerate the development of
innovative, bio-based solutions to the world's most pressing
environmental challenges.
About Ginkgo Bioworks
Ginkgo is building a platform to
enable customers to program cells as easily as we can program
computers. The company's platform is enabling biotechnology
applications across diverse markets, from food and agriculture to
industrial chemicals to pharmaceuticals. Ginkgo has also actively
supported a number of COVID-19 response efforts, including K-12
pooled testing, vaccine manufacturing optimization and therapeutics
discovery. In May 2021, Ginkgo
announced a business combination with Soaring Eagle Acquisition
Corp. (Nasdaq: SRNG), which, if completed, will result in Ginkgo,
through a parent entity, Ginkgo Bioworks Holdings, Inc., becoming a
public company. The transaction is expected to close in the third
quarter of 2021, subject to regulatory and shareholder approvals,
and other customary closing conditions. For more information, visit
www.ginkgobioworks.com.
MEDIA CONTACT:
press@ginkgobioworks.com
INVESTOR CONTACTS:
investors@ginkgobioworks.com
About Givaudan
Givaudan is a global leading company in
taste and wellbeing, and fragrance and beauty. With its heritage
stretching back over 250 years, the Company has a long history of
innovating scents and tastes. From a favourite drink to your daily
meal, from prestige perfumes to cosmetics and laundry care, its
creations inspire emotions and delight millions of consumers the
world over. The Company is committed to driving purpose-led,
long-term growth while leading the way to improve happiness and
health for people and nature. In the fiscal year 2020, the Company
employed almost 16,000 people worldwide and achieved sales of
CHF 6.3 billion and a free cash flow
of 12.8% of sales. Let's imagine together on www.givaudan.com.
ADDITIONAL LEGAL INFORMATION
Forward-Looking Statements Legend of Ginkgo
This
document contains certain forward-looking statements within the
meaning of the U.S. federal securities laws with respect to the
proposed transaction between Ginkgo and Soaring Eagle, including
statements regarding the benefits of the transaction, the
anticipated timing of the transaction, the services offered by
Ginkgo and the markets in which it operates, and Ginkgo's projected
future results. These forward-looking statements generally are
identified by the words "believe," "project," "expect,"
"anticipate," "estimate," "intend," "strategy," "future,"
"potential," "opportunity," "plan," "may," "should," "will,"
"would," "will be," "will continue," "will likely result," and
similar expressions. Forward-looking statements are predictions,
projections and other statements about future events that are based
on current expectations and assumptions and, as a result, are
subject to risks and uncertainties. Many factors could cause actual
future events to differ materially from the forward-looking
statements in this document, including but not limited to: (i) the
risk that the transaction may not be completed in a timely manner
or at all, which may adversely affect the price of Soaring Eagle's
securities, (ii) the risk that the transaction may not be completed
by Soaring Eagle's business combination deadline and the potential
failure to obtain an extension of the business combination deadline
if sought by Soaring Eagle, (iii) the failure to satisfy the
conditions to the consummation of the transaction, including the
adoption of the agreement and plan of merger by the shareholders of
Soaring Eagle and Ginkgo, the satisfaction of the minimum trust
account amount following redemptions by Soaring Eagle's public
shareholders and the receipt of certain governmental and regulatory
approvals, (iv) the lack of a third party valuation in determining
whether or not to pursue the proposed transaction, (v) the
occurrence of any event, change or other circumstance that could
give rise to the termination of the agreement and plan of merger,
(vi) the effect of the announcement or pendency of the transaction
on Ginkgo business relationships, performance, and business
generally, (vii) risks that the proposed transaction disrupts
current plans of Ginkgo and potential difficulties in Ginkgo
employee retention as a result of the proposed transaction, (viii)
the outcome of any legal proceedings that may be instituted against
Ginkgo or against Soaring Eagle related to the agreement and plan
of merger or the proposed transaction, (ix) the ability to maintain
the listing of Soaring Eagle's securities on Nasdaq, (x) volatility
in the price of Soaring Eagle's securities due to a variety of
factors, including changes in the competitive and highly regulated
industries in which Ginkgo plans to operate, variations in
performance across competitors, changes in laws and regulations
affecting Ginkgo's business and changes in the combined capital
structure, (xi) the ability to implement business plans, forecasts,
and other expectations after the completion of the proposed
transaction, and identify and realize additional opportunities, and
(xii) the risk of downturns in demand for products using synthetic
biology. The foregoing list of factors is not exhaustive. You
should carefully consider the foregoing factors and the other risks
and uncertainties described in the "Risk Factors'' section of
Soaring Eagle's proxy statement/prospectus relating to the
transaction, and in Soaring Eagle's other filings with the SEC.
Soaring Eagle and Ginkgo caution that the foregoing list of factors
is not exclusive. Soaring Eagle and Ginkgo caution readers not to
place undue reliance upon any forward-looking statements, which
speak only as of the date made. Neither Soaring Eagle nor Ginkgo
undertake or accept any obligation or undertaking to release
publicly any updates or revisions to any forward-looking statements
to reflect any change in its expectations or any change in events,
conditions or circumstances on which any such statement is
based.
Additional Information and Where to Find It
This
document relates to a proposed transaction between Ginkgo and
Soaring Eagle. This document does not constitute an offer to sell
or exchange, or the solicitation of an offer to buy or exchange,
any securities, nor shall there be any sale of securities in any
jurisdiction in which such offer, sale or exchange would be
unlawful prior to registration or qualification under the
securities laws of any such jurisdiction. In connection with the
proposed transaction, Soaring Eagle filed a proxy statement on
August 13, 2021. The proxy statement
has been sent to all Soaring Eagle shareholders of record as of the
close of business on August 10, 2021.
Soaring Eagle also will file other documents regarding the proposed
transaction with the SEC. Before making any voting decision,
investors and security holders of Soaring Eagle and Ginkgo are
urged to read the registration statement, the proxy
statement/prospectus and all other relevant documents filed or that
will be filed with the SEC in connection with the proposed
transaction as they become available because they will contain
important information about the proposed transaction.
Investors and security holders may obtain free copies of the
proxy statement/prospectus and all other relevant documents filed
or that will be filed with the SEC by Soaring Eagle through the
website maintained by the SEC at www.sec.gov. In addition, the
documents filed by Soaring Eagle may be obtained free of charge by
written request to Soaring Eagle at 955 Fifth Avenue, New York, NY, 10075, Attention: Eli Baker, Chief Financial Officer, (310)
209-7280.
Participants in Solicitation
Soaring Eagle's and
Ginkgo and their respective directors and officers may be deemed to
be participants in the solicitation of proxies from Soaring Eagle's
shareholders in connection with the proposed transaction.
Information about Soaring Eagle's directors and executive officers
and their ownership of Soaring Eagle's securities is set forth in
Soaring Eagle's filings with the SEC. To the extent that holdings
of Soaring Eagle's securities have changed since the amounts
printed in Soaring Eagle's proxy statement, such changes have been
or will be reflected on Statements of Change in Ownership on Form 4
filed with the SEC. Additional information regarding the interests
of those persons and other persons who may be deemed participants
in the proposed transaction may be obtained by reading the proxy
statement/prospectus regarding the proposed transaction when it
becomes available. You may obtain free copies of these documents as
described in the preceding paragraph.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/ginkgo-bioworks-and-givaudan-enter-multi-program-collaboration-to-produce-a-series-of-ingredients-301364650.html
SOURCE Ginkgo Bioworks